<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39435457</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1178-6973</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Infection and drug resistance</Title><ISOAbbreviation>Infect Drug Resist</ISOAbbreviation></Journal><ArticleTitle>Clinical Features and Prognosis of Patients with COVID-19 and B-Cell Non-Hodgkin Lymphoma.</ArticleTitle><Pagination><StartPage>4501</StartPage><EndPage>4510</EndPage><MedlinePgn>4501-4510</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/IDR.S477107</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">There is a lack of real-world data on the epidemiology, clinical manifestations, treatment effects, and prognosis of coronavirus disease 2019 (COVID-19) in patients with B-cell non-Hodgkin lymphoma (B-NHL). This study aimed to investigate the clinical features and prognostic factors of COVID-19 in patients with B-NHL.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="UNASSIGNED">This study included individuals diagnosed with B-NHL who were also diagnosed with COVID-19 and hospitalized. A retrospective analysis was conducted, and univariate and multivariate logistic regression were used to identify independent factors affecting the duration of the positive-to-negative transition of COVID-19 nucleic acid test results and prognoses. Receiver operating characteristic curves were used to assess diagnostic accuracy and determine the optimal threshold.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Among 80 patients with COVID-19 and B-NHL, relapsed or refractory lymphoma and diffuse large B-cell lymphoma (DLBCL) accounted for 13.8% and 65% of cases, respectively. The mean age was 60.4 ± 13.0 years, and 50% of patients were women. The median duration of the positive-to-negative transition was 14 days (interquartile range [IQR], 17.2), and the median hospitalization duration was 12 days (IQR, 13). The rate of severe disease was 26.25%, and the 28-day mortality rate was 10.00%. Univariate and multivariate logistic regression analyses revealed that pathological classification of B-NHL, infection with COVID-19 within 3 months after the last dose of anti-CD20 monoclonal antibodies, and corticosteroid use were independent factors associated with a prolonged duration of the positive-to-negative transition. Compared with patients with DLBCL or FL and COVID-19, patients with B-NHL had longer nucleic acid test transition durations and higher rates of severe disease and mortality.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">In patients with B-NHL, infection with COVID-19 within 3 months after treatment with anti-CD20 monoclonal antibodies prolonged the positive-to-negative transition of nucleic acid test results and increased the risks of severe disease and 28-day mortality. Treatment with corticosteroids further prolonged this transition.</AbstractText><CopyrightInformation>© 2024 Lin et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Ya-Qing</ForeName><Initials>YQ</Initials><AffiliationInfo><Affiliation>Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan (Hangzhou) Hospital Affiliated to Shulan International Medical College, Zhejiang Shuren University, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Na</ForeName><Initials>N</Initials><Identifier Source="ORCID">0009-0007-7309-9143</Identifier><AffiliationInfo><Affiliation>Zhejiang Provincial General Hospital of the Chinese People's Armed Police Force, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yan-Li</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan (Hangzhou) Hospital Affiliated to Shulan International Medical College, Zhejiang Shuren University, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Jin-Bao</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0003-3711-8304</Identifier><AffiliationInfo><Affiliation>Department of Drug-Resistance Tuberculosis, Xi'an Chest Hospital, Xi'an, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Hai-Nv</ForeName><Initials>HN</Initials><AffiliationInfo><Affiliation>Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan (Hangzhou) Hospital Affiliated to Shulan International Medical College, Zhejiang Shuren University, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Infect Drug Resist</MedlineTA><NlmUniqueID>101550216</NlmUniqueID><ISSNLinking>1178-6973</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B-cell non-Hodgkin lymphoma</Keyword><Keyword MajorTopicYN="N">COVID-19 infection</Keyword><Keyword MajorTopicYN="N">clinical features</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>4</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39435457</ArticleId><ArticleId IdType="pmc">PMC11492921</ArticleId><ArticleId IdType="doi">10.2147/IDR.S477107</ArticleId><ArticleId IdType="pii">477107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Casetti IC, Borsani O, Rumi E. COVID-19 in patients with hematologic diseases. Biomedicines. 2022;10(12):3069. doi:10.3390/biomedicines10123069</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10123069</ArticleId><ArticleId IdType="pmc">PMC9775038</ArticleId><ArticleId IdType="pubmed">36551825</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SY, Wang YM, Liu M, Zhao L, Cao B. Migratory pulmonary ground glass opacities caused by SARS-CoV-2 infection in a patient on B-cell depletion therapy. Zhonghua Jie He He Hu Xi Za Zhi. 2023;46(12):1233–1239. doi:10.3760/cma.j.cn112147-20230809-00061</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn112147-20230809-00061</ArticleId><ArticleId IdType="pubmed">38044051</ArticleId></ArticleIdList></Reference><Reference><Citation>DeWolf S, Laracy JC, Perales MA, Kamboj M, van den Brink M, Vardhana S. SARS-CoV-2 in immunocompromised individuals. Immunity. 2022;55(10):1779–1798. doi:10.1016/j.immuni.2022.09.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2022.09.006</ArticleId><ArticleId IdType="pmc">PMC9468314</ArticleId><ArticleId IdType="pubmed">36182669</ArticleId></ArticleIdList></Reference><Reference><Citation>Kochneva ОL, Kislova M, Zhelnova EI, et al. COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study. Leuk Lymphoma. 2022;63(7):1607–1616. doi:10.1080/10428194.2022.2034157</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10428194.2022.2034157</ArticleId><ArticleId IdType="pubmed">35156528</ArticleId></ArticleIdList></Reference><Reference><Citation>Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol. 2010;47(2):187–198. doi:10.1053/j.seminhematol.2010.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.seminhematol.2010.01.002</ArticleId><ArticleId IdType="pubmed">20350666</ArticleId></ArticleIdList></Reference><Reference><Citation>Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737–e745. doi:10.1016/S2352-3026(20)30251-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(20)30251-9</ArticleId><ArticleId IdType="pmc">PMC7426107</ArticleId><ArticleId IdType="pubmed">32798473</ArticleId></ArticleIdList></Reference><Reference><Citation>Tudesq JJ, Cartron G, Rivière S, et al. Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders. Autoimmun Rev. 2018;17(2):115–124. doi:10.1016/j.autrev.2017.11.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2017.11.015</ArticleId><ArticleId IdType="pubmed">29180125</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaitzsch E, Passerini V, Khatamzas E, et al. COVID-19 in patients receiving CD20-depleting immunochemotherapy for B-cell lymphoma. Hemasphere. 2021;5(7):e603. doi:10.1097/HS9.0000000000000603</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HS9.0000000000000603</ArticleId><ArticleId IdType="pmc">PMC8240782</ArticleId><ArticleId IdType="pubmed">34235400</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcacci G, Fiorentino G, Volzone F, et al. Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab. Infect Agent Cancer. 2021;16(1):38. doi:10.1186/s13027-021-00376-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13027-021-00376-1</ArticleId><ArticleId IdType="pmc">PMC8170447</ArticleId><ArticleId IdType="pubmed">34078415</ArticleId></ArticleIdList></Reference><Reference><Citation>Hueso T, Pouderoux C, Péré H, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020;136(20):2290–2295. doi:10.1182/blood.2020008423</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020008423</ArticleId><ArticleId IdType="pmc">PMC7702482</ArticleId><ArticleId IdType="pubmed">32959052</ArticleId></ArticleIdList></Reference><Reference><Citation>Avanzato VA, Matson MJ, Seifert SN, et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell. 2020;183(7):1901–1912.e9. doi:10.1016/j.cell.2020.10.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.049</ArticleId><ArticleId IdType="pmc">PMC7640888</ArticleId><ArticleId IdType="pubmed">33248470</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore JL, Ganapathiraju PV, Kurtz CP, Wainscoat B. A 63-year-old woman with a history of non-Hodgkin lymphoma with persistent SARS-CoV-2 infection who was seronegative and treated with convalescent plasma. Am J Case Rep. 2020;21:e927812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7542548</ArticleId><ArticleId IdType="pubmed">33009361</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda H, Tsukune Y, Watanabe N, et al. Persistent COVID-19 pneumonia and failure to develop anti-SARS-CoV-2 antibodies during rituximab maintenance therapy for follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2020;20(11):774–776. doi:10.1016/j.clml.2020.08.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clml.2020.08.017</ArticleId><ArticleId IdType="pmc">PMC7442568</ArticleId><ArticleId IdType="pubmed">32933879</ArticleId></ArticleIdList></Reference><Reference><Citation>Martínez-Chinchilla C, Vazquez-Montero L, Palazón-Carrión N, et al. Persistence of SARS-CoV-2 infection in severely immunocompromised patients with complete remission B-cell lymphoma and anti-CD20 monoclonal antibody therapy: a case report of two cases. Front Immunol. 2022;13:860891. doi:10.3389/fimmu.2022.860891</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.860891</ArticleId><ArticleId IdType="pmc">PMC9046988</ArticleId><ArticleId IdType="pubmed">35493500</ArticleId></ArticleIdList></Reference><Reference><Citation>Drouin AC, Theberge MW, Liu SY, et al. Successful clearance of 300 day SARS-CoV-2 infection in a subject with B-cell depletion associated prolonged (B-DEAP) COVID by REGEN-COV anti-spike monoclonal antibody cocktail. Viruses. 2021;13(7):1202. doi:10.3390/v13071202</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13071202</ArticleId><ArticleId IdType="pmc">PMC8310246</ArticleId><ArticleId IdType="pubmed">34201591</ArticleId></ArticleIdList></Reference><Reference><Citation>Franceschini E, Pellegrino M, Todisco V, et al. Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab. Infection. 2023;51(5):1577–1581. doi:10.1007/s15010-023-02039-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-023-02039-2</ArticleId><ArticleId IdType="pmc">PMC10115373</ArticleId><ArticleId IdType="pubmed">37076752</ArticleId></ArticleIdList></Reference><Reference><Citation>Visco C, Marcheselli L, Mina R, et al. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. Blood Adv. 2022;6(1):327–338. doi:10.1182/bloodadvances.2021005691</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021005691</ArticleId><ArticleId IdType="pmc">PMC8516438</ArticleId><ArticleId IdType="pubmed">34644385</ArticleId></ArticleIdList></Reference><Reference><Citation>Łącki S, Wyżgolik K, Nicze M, Georgiew-Nadziakiewicz S, Chudek J, Wdowiak K. Low symptomatic COVID-19 in an elderly patient with follicular lymphoma treated with rituximab-based immunotherapy: a case report. World J Clin Cases. 2021;9(18):4859–4865. doi:10.12998/wjcc.v9.i18.4859</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v9.i18.4859</ArticleId><ArticleId IdType="pmc">PMC8223830</ArticleId><ArticleId IdType="pubmed">34222459</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie H, Zhang J, Luo R, et al. IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients. BMC Immunol. 2024;25(1):5. doi:10.1186/s12865-024-00596-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12865-024-00596-1</ArticleId><ArticleId IdType="pmc">PMC10788029</ArticleId><ArticleId IdType="pubmed">38218761</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Cruz-Benito B, Lázaro-Del Campo P, Ramírez-López A, et al. Managing the front- line treatment for diffuse large B cell lymphoma and high-grade B cell lymphoma during the COVID-19 outbreak. Br J Haematol. 2020;191(3):386–389. doi:10.1111/bjh.17066</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17066</ArticleId><ArticleId IdType="pmc">PMC7436686</ArticleId><ArticleId IdType="pubmed">32762043</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohn M, Alsuliman T, Lamure S, et al. Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak. Leuk Lymphoma. 2022;63(11):2686–2690. doi:10.1080/10428194.2022.2086249</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10428194.2022.2086249</ArticleId><ArticleId IdType="pubmed">35719107</ArticleId></ArticleIdList></Reference><Reference><Citation>Comprehensive group of the Joint Prevention and Control Mechanism of The State Council. Guidelines for prevention and control of coronavirus disease 2019 (10th edition). Chin J Viral Dis. 2023;13(2):108–110.</Citation></Reference><Reference><Citation>Zhuang X, Zheng Y, Wei S, et al. Can the nucleic acid Ct value of discharged patients infected with SARS-CoV-2 Omicron variant be 35?—A retrospective study on fluctuation of nucleic acid Ct values in SNIEC mobile cabin hospital. Front Cell Infect Microbiol. 2022;12:1059880. doi:10.3389/fcimb.2022.1059880</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.1059880</ArticleId><ArticleId IdType="pmc">PMC9806225</ArticleId><ArticleId IdType="pubmed">36601305</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadi S, Bazargan M, Elahi R, Esmaeilzadeh A. Immune evasion of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2); molecular approaches. Mol Immunol. 2023;156:10–19. doi:10.1016/j.molimm.2022.11.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2022.11.020</ArticleId><ArticleId IdType="pmc">PMC9684099</ArticleId><ArticleId IdType="pubmed">36857806</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacchiarini N, Sawyer C, Williams C, et al. Epidemiological analysis of the first 1000 cases of SARS-CoV-2 lineage BA.1 (B.1.1.529, Omicron) compared with co-circulating Delta in Wales, UK. Influenza Other Respir Viruses. 2022;16(6):986–993. doi:10.1111/irv.13021</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.13021</ArticleId><ArticleId IdType="pmc">PMC9350272</ArticleId><ArticleId IdType="pubmed">35822273</ArticleId></ArticleIdList></Reference><Reference><Citation>Mella-Torres A, Escobar A, Barrera-Avalos C, et al. Epidemiological characteristics of Omicron and Delta SARS-CoV-2 variant infection in Santiago, Chile. Front Public Health. 2022;10:984433. doi:10.3389/fpubh.2022.984433</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.984433</ArticleId><ArticleId IdType="pmc">PMC9634544</ArticleId><ArticleId IdType="pubmed">36339233</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102538</ArticleId><ArticleId IdType="pubmed">32105632</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Zhang Y, Huang B, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020;182(3):713–721.e9. doi:10.1016/j.cell.2020.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.06.008</ArticleId><ArticleId IdType="pmc">PMC7275151</ArticleId><ArticleId IdType="pubmed">32778225</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow RD, Majety M, Chen S. The aging transcriptome and cellular landscape of the human lung in relation to SARS-CoV-2. Nat Commun. 2021;12(1):4. doi:10.1038/s41467-020-20323-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20323-9</ArticleId><ArticleId IdType="pmc">PMC7782551</ArticleId><ArticleId IdType="pubmed">33397975</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JT, Leung K, Bushman M, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med. 2020;26(4):506–510. doi:10.1038/s41591-020-0822-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0822-7</ArticleId><ArticleId IdType="pmc">PMC7094929</ArticleId><ArticleId IdType="pubmed">32284616</ArticleId></ArticleIdList></Reference><Reference><Citation>Duléry R, Lamure S, Delord M, et al. Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021;96(8):934–944. doi:10.1002/ajh.26209</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26209</ArticleId><ArticleId IdType="pmc">PMC8212109</ArticleId><ArticleId IdType="pubmed">33909916</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajima Y, Ogai A, Furukawa K, et al. Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient. J Infect Chemother. 2021;27(2):387–389. doi:10.1016/j.jiac.2020.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiac.2020.12.001</ArticleId><ArticleId IdType="pmc">PMC7836222</ArticleId><ArticleId IdType="pubmed">33328135</ArticleId></ArticleIdList></Reference><Reference><Citation>Tepasse PR, Hafezi W, Lutz M, et al.Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. Br J Haematol. 2020;190(2):185–188. doi:10.1111/bjh.16896</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.16896</ArticleId><ArticleId IdType="pmc">PMC7300950</ArticleId><ArticleId IdType="pubmed">32557623</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>